The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Durata Therapeutics, Inc. | COM | 26658A107 | 40,800 | 3,030,175 | SH | SOLE | 3,030,175 | 0 | 0 | ||
| Quintiles Transnatio Hldgs I | COM | 74876Y101 | 58,600 | 1,153,773 | SH | SOLE | 1,153,773 | 0 | 0 | ||
| Chimerix, Inc. | COM | 16934W106 | 27,900 | 1,222,943 | SH | SOLE | 1,222,943 | 0 | 0 | ||
| MEI Pharma, Inc. | COM NEW | 55279B202 | 8,600 | 770,000 | SH | SOLE | 770,000 | 0 | 0 | ||
| Sorrento Therapeutics, Inc | COM NEW | 83587F202 | 8,000 | 620,700 | SH | SOLE | 620,700 | 0 | 0 | ||